Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium

On February 25, 2019 Nektar Therapeutics (Nasdaq: NKTR) reported that it will webcast an analyst and investor conference call with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO (Free ASCO Whitepaper)-SITC Clinical Immuno-Oncology Symposium (Press release, Nektar Therapeutics, FEB 25, 2019, https://www.prnewswire.com/news-releases/nektar-therapeutics-to-webcast-conference-call-for-analysts-and-investors-at-the-2019-asco-sitc-clinical-immuno-oncology-symposium-300801596.html [SID1234533642]). The event will follow Friday’s oral presentation by Dr. Diab of preliminary data from the ongoing dose-escalation stage of the REVEAL Phase 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the Analyst Call:

Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time

Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)

Passcode: 6970019

The conference call will include lead investigator on the REVEAL study, Dr. Adi Diab, Assistant Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference call can be accessed through a link that is posted on the Investors section of the Nektar website at View Source The event will also be available for replay for two weeks on the company’s website, www.nektar.com.

Details on the Oral Presentation at ASCO (Free ASCO Whitepaper)-SITC:

Abstract Title: "Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8

agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid

tumors (REVEAL Phase Ib/II Trial)"

Abstract: #28

Presenter: Dr. Adi Diab, MD Anderson Cancer Center

Session: Oral Abstract Session B

Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time